Clinical and regulatory intelligence for CNS Lymphoma with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Assets: 3

Relevant assets

nivolumab →

Phase →

Rituximab →

Relevant companies

Ono Pharmaceutical →

Recent signals(3)

ClinicalJuly 23, 2026

Phase I Trial of Lenalidomide and Nivolumab in Primary CNS Lymphoma

A phase I trial is underway to evaluate the safety and efficacy of lenalidomide combined with nivolumab in treating primary CNS lymphoma.

ClinicalJuly 17, 2026

Phase I Trial on Hyperpolarized Imaging for CNS Lymphoma Shows Feasibility

A phase I trial is assessing the feasibility and safety of hyperpolarized carbon-13 pyruvate MRI in diagnosing primary CNS lymphoma.

ClinicalJune 29, 2026

Tirabrutinib vs R-TMZ in Relapsed/Refractory PCNSL: IGNITE Study Launched

The IGNITE study is evaluating tirabrutinib's efficacy and safety against the R-TMZ regimen in relapsed/refractory PCNSL.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

CNS Lymphoma →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.